Dr MeiLan Han, of the University of Michigan, Ann Arbor, highlights studies in chronic obstructive pulmonary disease (COPD) presented at the CHEST 2021 Annual Meeting. Dr Han first reports on a study ...

India has the second-highest incidence of chronic obstructive pulmonary disease (CoPD) in the world, after China. What you need to know about CoPD and the cost of treatment for the chronic lung ...

COPD mortality in China decreased from 2014 to 2021, but the disease burden remains high in underdeveloped regions. COPD is mainly caused by air pollution and smoking, with older adults being the most ...

Inhalers Single-inhaler triple therapy is associated with a favorable benefit-risk profile compared with dual therapy for patients with symptomatic COPD and a history of exacerbations. Single-inhaler ...

COPD remains the fourth leading global cause of death, with 3.5 million fatalities reported in 2021. As pollution worsens, especially in Delhi NCR, experts warn that smoking, secondhand smoke and ...

Eosinophil Granulocytes COPD Patients with COPD who exhibit low blood eosinophil counts had no change in exacerbations or survival compared with patients with typical counts. Patients with chronic ...

After another swing and a miss for AstraZeneca's Fasenra in chronic obstructive pulmonary disease (COPD), the company is pivoting to other options in its portfolio that might have potential to treat ...

Many people with chronic obstructive pulmonary disease (COPD) experience severe fatigue that can limit their ability to perform daily activities. A 2021 review found fatigue was a symptom of COPD in ...

The GOLD 2023 and 2024 reports recommend that health professionals consider triple therapy (TT) entailing combined use of a long-acting β 2 agonist (LABA), a long-acting muscarinic antagonist (LAMA), ...